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Summary. A 62-year-old woman presented with
abdominal discomfort. Imaging studies showed a tumor
in the pancreatic tail. At contrast-enhanced CT and
macroscopy, the tumor showed cystic, solid and
hemorrhagic areas. Histologically, the tumor was well-
circumscribed and entirely encapsulated. Some of the
tumor cells in the cystic areas were reminiscent of acinar
cells, and the majority was arranged in a solid growth
pattern. Immunohistochemistry revealed >30% positivity
for chymotrypsin, chromogranin A, synaptophysin, and
CD56. The diagnosis of a mixed acinar-neuroendocrine
carcinoma (MAEC) was made. Review of the English
language literature revealed 44 previously published
cases of resected MAECs. We found that, compared to
pure acinar cell carcinoma, patients with MAEC have a
slightly higher age and are less frequently males, as the
male/female ratio was almost equal. The histogenesis of
MAEC is still controversial. Due to the small number of
cases it is at present not possible to define an evidence-
based optimal treatment strategy for these patients.
Key words: Mixed acinar-neuroendocrine carcinoma,
Pancreatic cancer, Acinar cell carcinoma, Immuno-
histochemistry
Introduction
The majority of pancreatic cancers fall into four
distinct categories: ductal adenocarcinoma, intraductal
papillary mucinous neoplasm with an associated
invasive carcinoma, acinar cell carcinoma (ACC), and
neuroendocrine neoplasm (Fukushima et al., 2010).
Acinar cell carcinoma is a rare tumor accounting for
approximately 1% of pancreatic exocrine tumors
(Klimstra et al., 2010). Although it is well established
that roughly one-third of acinar cell carcinomas may
express neuroendocrine markers (Klimstra et al., 1994;
Ohike et al., 2004), their neuroendocrine component is
usually limited to a few scattered cells. When the
neuroendocrine cells exceed 30% of the tumor, it is
classified as mixed acinar-neuroendocrine carcinoma
(MAEC) (Fukushima et al., 2010). MAECs are
exceedingly rare. We present a case of a 62-year-old
woman who was treated with a left-sided pancreatic
resection with the post-operative diagnosis of MAEC.
Because it is not known whether MAECs have
characteristic clinicopathological features that
distinguish them from ACCs, we reviewed the existing
literature.
Material and methods
Case report
A 62-year-old woman presented with abdominal
discomfort over a one-month period. Pancreatic exocrine
and endocrine symptoms were absent. The physical
examination and blood tests were in the normal range,
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serum amylase was 27 U/L preoperatively. Serum levels
of AFP and NSE were not analyzed. She was referred for
an abdominal ultrasound which showed a large, well-
circumscribed tumor, measuring 5 cm in diameter and
located in the pancreatic tail. Subsequent abdominal
contrast-enhanced computed tomography (CT) of the
abdomen (Fig. 1) and endoscopic ultrasound confirmed
the findings, as both were indicative of a cystic or solid-
pseudopapillary neoplasm. The patient underwent a left-
sided pancreatic resection with splenectomy and
postoperative adjuvant chemotherapy with gemcitabine
targeting the ACC component. She is currently well,
now 12 months after the operation, without evidence of
recurrence.
Immunohistochemistry
The resection specimen was fixed in formalin and
selected areas of interest were embedded in paraffin. 4
µm thick sections from these formalin-fixed, paraffin-
embedded tissue blocks were stained with hematoxylin
& eosin. For immunohistochemistry, the sections were
mounted on FLEX IHC slides (Dako, Glostrup,
Denmark), dried at room temperature, and incubated at
60°C for 60 minutes before immunostaining. The
immunohistochemical staining procedure was automated
using the BenchMark Ultra immunostainer (Ventana
Medical Systems, Tucson, AZ), with the OptiView-DAB
detection kit (Ventana Medical Systems, Tucson, AZ).
Primary antibodies, dilutions, incubation times and
epitope retrieval procedures were as specified in Table 1.
Nuclear counter staining was performed with the
BenchMark Ultra instrument, using Hematoxylin II
(Ventana Medical Systems, Tucson, AZ). Finally, slides
were washed, dehydrated, and coverslipped using a
Tissue-Tek Film coverslipper (Sakura, Alphen aan den
Rijn, The Netherlands).
Electron microscopy
For the electron microscopic examination, tissue
fragments of 1 mm3 were cut with a scalpel from distinct
areas in the relevant paraffin blocks chosen from the HE-
stained sections. The tissue was then reprocessed using
xylene dewaxing, specimen rehydration with ethanol,
post-fixation in glutaraldehyde and then rehydrated
before being infiltrated with epon. The hardened epon
blocks were trimmed and sectioned into 1 µm slices with
glass knifes attached to an ultramicrotome. These
sections were then stained with Toluidine blue and
examined with a light microscope in order to identify
areas of interest. 6 nm sections were cut from these areas
and mounted on a grid for electron microscopic
examination. 
Literature review
PubMed searches using the terms “mixed acinar-
neuroendocrine carcinoma AND pancreas”, “MAEC
AND pancreas”, “Mixed adeno-neuroendocrine
carcinoma AND pancreas”, “MANEC AND pancreas”
and “acinar cell carcinoma AND pancreas” were
performed. Moreover, we found relevant publications by
cross referencing. All English language articles reporting
cases with MAECs and giving at least age and sex of the
patients were included in the review. Papers where the
diagnosis of MAEC was based on cytology alone were
excluded.
Results
Macroscopy
Macroscopically, a tumor in the pancreatic tail was
observed, measuring 5.2 cm in largest diameter. The cut
surface revealed a large cystic area, 2 cm in greatest
dimension, and solid areas. The color was pale and fawn,
interchanging with tan and dark-brown areas.
Hemorrhage and degenerative cystic changes were also
observed (Fig. 2). 
Microscopy and immunohistochemistry
The tumor was well-circumscribed and entirely
encapsulated. The tumor cells in the cystic areas were
reminiscent of acinar cells, which focally were arranged
in an almost acinar pattern (Fig. 3A). The size of their
nuclei varied only slightly, and distinct nucleoli were
present in some of them. At immunohistochemistry,
more than 30% of these cells strongly expressed
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Fig. 1. Contrast-enhanced CT scan of the abdomen showing a well-
circumscribed tumor with cystic areas in the pancreatic tail. There is no
involvement of the lymph nodes.
Fig. 2. The cut surface of the left-sided pancreatic resection specimen. A. Solid areas with a pale and fawn color interchanging with tan and dark-brown
areas. B. Hemorrhage and degenerative cystic changes are also seen. A larger cystic area is shown (arrows).
Table 1. Antibodies used for immunohistochemical staining.
Antigen Company Clone Code nr. Dilution Epitope
retrieval Incubation
Detection
system
AFP Dako - A0008 2000 CC1_32_100 16 min/36C OptiView-DAB
Alpha-1
antitrypsin, 
Z-variant
Hycult Biotechnologie 2C1 (mouse), monoclonal HM2289 200
CC1_32_95 
+ Protease 
3/4 min.
16 min/36C OptiView-DAB
BCL10 Dako 151 M7260 25 CC1_32_100 20 min/36C OptiView-DAB
Beta catenin BD Transduction Laboratories 14 (mouse), monoclonal 610153 500 CC1_48_100 32 min/36C OptiView-DAB
Calretinin Ventana Medical Systems SP65 (rabbit), monoclonal 790-4467 RTU CC1_32_100 12 min/36C OptiView-DAB
CD10 Novocastra 56C6 (mouse), monoclonal NCL-L-CD10-270 10 CC1_32_100 32 min/36C OptiView-DAB
CD56 Cell Marque MRQ-42 (rabbit), monoclonal 156R 500 CC1_32_100 32 min/36C OptiView-DAB
CEA-mono Zymed Col-1, Carcinoembryonic Antigen (CD66e) 18-0057 200 CC1_32_100 32 min/36C OptiView-DAB
Chromogranin A Ventana Medical Systems LK2H10 (Mouse), monoclonal 760-2519 RTU CC1_24_100 24 min/36C OptiView-DAB
Chymotrypsin Acris Antibodies GmbH 4E1 (mouse), monoclonal BM293 200 CC2_32_91 24 min/36C OptiView-DAB
CK7 Ventana Medical Systems SP52 (rabbit), monoclonal 790-4462 RTU CC1_48_100 32 min/36C OptiView-DAB
CK8 Epitomics EP17 (rabbit), monoclonal AC-0007 100 CC1_32_100 32 min/36C OptiView-DAB
CK19 Ventana Medical Systems A53-B/A2.26 (mouse), monoclonal 760-4281 RTU CC1_32_100 32 min/36C OptiView-DAB
CK20 Ventana Medical Systems SP33 (rabbit), monoclonal 790-4431 RTU CC1_32_100 12 min/36C OptiView-DAB
Gastrin Ventana Medical Systems Polyclonal (rabbit) 760-2643 RTU Protease 1/4 min. 16 min/36C OptiView-DAB
Glucagon Epitomics EP74 (rabbit), monoclonal AC-0074A 200 CC1_32_100 8 min./36C OptiView-DAB
Insulin NovoCastra 2D11-H5 (mouse), monoclonal NCL-INSULIN 100 CC1_16_100 24 min/36C OptiView-DAB
Ki67 Ventana Medical Systems 30-9 (rabbit), monoclonal 790-4286 RTU CC1_48_100 12 min/36C OptiView-DAB
NSE Dako BBS/NC/VI-H14 (mouse), monoclonal M0873 1000 CC1_32_100 12 min/36C OptiView-DAB
Serotonin Dako 5HT-H209 (mouse), monoclonal M0758 50 CC2_32_91 16 min/36C OptiView-DAB
Somatostatin
Receptor 2 Epitomics EP149 (UMB1) (rabbit), monoclonal AC-0162 400 CC1_32_100 32 min/36C OptiView-DAB
Somatostatin EuroProxima B18-1 (rabbit), polyclonal B18-1 10000 CC1_32_100 12 min/36C OptiView-DAB
Synaptophysin NovoCastra 27G12 (mouse), monoclonal NCL-L-SYNAP-299 50 CC1_48_100 32 min/36C OptiView-DAB
Trypsin Chemicon-Millipore Internat. Inc. MAB1482 (mouse), monoclonal MAB1482 100 - - OptiView-DAB
Vimentin Ventana Medical Systems V9 (mouse), monoclonal 790-2917 RTU CC1_32_100 16 min/36C OptiView-DAB
VIP EuroProxima 6-28 (rabbit), polyclonal 2263B34-1 1000 CC1_32_100 16 min/36C OptiView-DAB
C, Celsius degrees; CC1, Cell Conditioning Solution 1 (pH 8.5) (Ventana Medical Systems); CC2, Cell Conditioning Solution 2 (pH 6.0) (Ventana
Medical Systems); CCx,_minutes incubated_/ degrees Celcius; RTU, ready-to-use.
chymotrypsin (Fig. 3B), and the neuroendocrine markers
synaptophysin (Fig. 3C), chromogranin A and CD56.
Also in the solid areas (Fig. 4A), the tumor cells
expressed chymotrypsin (Fig. 4B) as well as
synaptophysin (Fig. 4C), CD56, and chromogranin A.
Scattered apoptotic tumor cells were seen. The stroma
was very sparse and contained small vessels. A few
scattered microcystic formations with hemorrhage were
observed. Moreover, there were areas with
hemosiderophages. Angioinvasion and perineural
invasion were absent. Eight lymph nodes were examined
microscopically and without metastases.
Immunohistochemistry revealed, in addition to the
already mentioned markers, expression of CD10 and
CK8. There was nuclear positivity for beta-catenin in a
significant proportion of the tumor cells, especially in
close proximity to smaller vessels, but positivity was
diffusely present throughout the tumor (Fig. 4D).
Trypsin (Fig. 4E) and BCL 10 (Fig. 4F) both showed a
diffuse and strong positivity throughout the tumor. The
Ki-67 index was 22%, classifying the neuroendocrine
component as a grade 3 tumor, according to the WHO
classification 2010 (Rindi et al., 2010). Distinct nucleoli
as well as “salt and pepper” speckled nuclei were
observed in some of the tumor cells (Fig. 5A). There was
no expression of AFP, alpha-1 antitrypsin, calretinin,
CEA-mono, CK7, CK19, CK20, gastrin, glucagon,
insulin, NSE, serotonin, somatostatin, somatostatin
receptor 2, vimentin, or VIP. Based on these findings,
the diagnosis of a MAEC was made. 
Electron microscopy
Ultrastructually, the tumor cells were of variable size
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Table 2. Symptoms, age, sex, localization, treatment, follow up, and survival in the 45 published histological cases of MAECs.
Study n Symptoms
Age*
[range],
sex
Location, diameter* 
(cm) [range] Type of surgery
Follow-up* 
in months
[range]
Patients alive
at time of
publication
LaRosa et al., 2012 (USA,
France, Japan, Italy) 12
Abdominal pain, 
weight loss
62.3 [37-
88], 7M, 5F
4 head
1 head/body
1 body
1 body/tail
4 tail
1 †
8.8 cm [2.8-19.5]
NA 24.75 [6-111] 6
Ohike et al., 2004 (Germany) 6 Abdominal pain 51.3 [16-65], 2M, 4F
No predilection, 
8.2 cm NA NA NA
Klimstra et al., 1994 (USA) 5
Abdominal pain
Incidental mass
Hematemesis
Incidental mass
Abdominal pain
81M
70M
64F
48F
70F
Tail, 3 cm
Multifocal, 10 cm
Head, 10 cm
Tail, 11 cm
Head, 10 cm
NA
NA
Biopsy, bypass
NA
Biopsy, bypass
9.6 [3-18] 3
Yu et al., 2013 (USA) 5
Abdominal pain, dyspepsia
Melena, weight loss
Abdominal pain, diarrhea
Abdominal pain, weight loss
Anorexia, jaundice
80M
89M
60M
74M
59M
Head, 19 cm
Head, 4.9 cm
Head, 21 cm
Body, 10 cm
Head, 7.5 cm
Debulking with splenectomy
Whipple's procedure
CGP‡
Distal pancreatectomy with splenectomy
Whipple’s procedure
13.7 
[2.5-36]§ 3
Cho et al., 1996 (Korea) 1 Jaundice 52F Uncinate process, 6 cm Whipple's procedure 12 1
Chung et al., 2010 (Korea) 1 Watery diarrhea 59F Tail, 8 cm PPPD || NA NA
Frank et al., 1998 (Germany) 1 Abdominal pain 61M Head/body Whipple's procedure 47 1
Ichijima et al., 1985 (Japan) 1 Asymptomatic 6F Tail, 8 cm Distal pancreatectomy 156 1
Imaoka et al., 2008 (Japan) 1 Lymphadenopathy 80M Head, 4 cm Whipple's procedure NA NA
Kobayashi et al., 2010 (Japan) 1 Asymptomatic 75M Tail Distal pancreatectomy 6 1
Kyriazi et al., 2009 (Greece) 1 Polyarthralgia 74M Head, 12 cm Whipple's procedure 3 1
Muramatsu et al., 2000 (Japan) 1 Weight loss 72M Body to tail, 13 cm Autopsy 3 0
Ogawa et al., 2000 (Japan) 1 Asymptomatic 50M Head, 3 cm PPPD 18 1
Ogbonna et al., 2013 (USA) 1 Abdominal pain 57F Body, 2.5 cm Pancreatectomy with splenectomy 0 1
Seth et al., 2008 (USA) 2 Abdominal pain NANA
NA, 12.5 cm
NA, 4.5 cm
Distal pancreatectomy
Pancreaticodoudenectomy
1
5
1
1
Shi et al., 2008 (China) 1 Whipple's triad 51F Tail, 1.2 cm Distal pancreatectomy 0 1
Soubra et al., 2011 (Lebanon) 1 Abdominal pain 52M Head Whipple's procedure 19 1
Ulich et al., 1982 (USA) 1 Asymptomatic 30F Head, 5.8 cm Whipple's procedure 0 1
Virlos et al., 2002 (UK) 1 Pruritus, weight loss 33M Head, 3.5 cm PPPD 15 1
Present case (Denmark) 1 Abdominal pain 62F Tail, 5.2 cm Pancreatectomy with splenectomy 12 1
NA, not available. * If more than one patient is reported, mean and [range] are given. † Information regarding tumor site for 1 patient was not available.
‡ CGP: Subtotal colectomy, partial gastrectomy, and 70% pancreatectomy. § 1 patient died of complications to surgery after 2.5 months. || PPPD:
Pylorus-preserving pancreaticoduodenectomy.
with a moderate to high amount of mitochondria, rough
endoplasmatic reticulum (rER) and secretory granules
(Fig. 5B). The secretory granules varied in size and had
a homogeneous electron dense appearance and bore a
resemblance to normal acinar secretory cells. The
cytoplasm contained two distinct types of secretory
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Fig. 3. Microscopic and immunohistochemical findings in the cystic part of pancreatic MAEC. A. Hematoxylin-eosin. B. Chymotrypsin. 
C. Synaptophysin.
Fig. 4. Microscopic and immunohistochemical findings in a solid area of pancreatic MAEC. Immunohistochemically, the mixed nature of the carcinoma
is illustrated with the following stains: A: Hematoxylin-eosin, B: Chymotrypsin, C: Synaptophysin, D: Beta-catenin, E: Trypsin, F: BCL10.
granules, with some cells containing larger (800 nm) and
some cells containing smaller granules (100 nm), but
most often the cells had intermediate features, with
moderate amounts of rER and dispersed granules
ranging 300-400 nm.
Literature review
A review of the English language literature revealed
44 previously reported cases of MAEC (Table 2).
Including the present case, patients with MAEC are
diagnosed at a mean age of 60.1 years (range 6-89
years). The male:female ratio is almost equal (56%
men). Most tumors are located in the pancreatic head
(51%), followed by the tail (37%). The mean diameter of
the tumors is 8.2 cm (range 1.2-21 cm). The follow-up
period ranged from 0 to 13 years. 26 of the 45 patients
were alive at the end of the various follow-up periods. 
Discussion
We present a case of pancreatic MAEC, an
exceedingly rare tumor type in the pancreas, and review
the existing English-language literature. Based on
macroscopy and immunohistochemistry, solid-
pseudopapillary neoplasia (SPN) represents one of the
most important differential diagnoses of MAEC. SPNs
are, however, predominantly found in young women,
whereas our patient was 62 years old. Moreover,
microscopically, the characteristic features of SPNs,
such as pseudopapillary growth pattern, eosinophilic
globules, foam cells, or longitudinal nuclear grooves,
were not present. Instead, the tumor cells had mixed
features of neuroendocrine and acinar cells. At
immunohistochemistry, the strong positivity for BCL10,
CK8, CK19, chromogranin A, chymotrypsin, trypsin,
and synaptophysin clearly indicated a tumor with mixed
features of ACC and NEC, as most of these markers
usually are negative or only focally positive in SPN. On
the other hand, markers often strongly expressed in SPN,
such as alpha-1 antitrypsin, NSE, and progesterone
receptor, were negative in the present case.
Ultrastructually, the present case also had distinctive
features, separating it further from SPN by the moderate
to high amounts of mitochondria, rough endoplasmatic
reticulum, and secretory granules, which are well known
characteristics of secretory cells. The secretory granules
varied in size and had a homogeneous, electron-dense
appearance resembling acinar secretory cells, as
described by others (Klimstra et al., 1994; Ichijima et al.,
1985). Histologically and immunohistochemically,
MAECs can show 3 different compositions: tumors with
1) separate acinar and neuroendocrine areas, 2) an
admixture of neuroendocrine and acinar cells, or 3) a
uniform but amphicrine cell population, showing
neuroendocrine and acinar cytological features (Klimstra
et al., 1992; Klöppel et al., 1996). In the present case, the
cystic as well as the solid areas revealed an admixture of
acinar as well as neuroendocrine features (Figs. 3, 4). 
The histogenesis of MAECs is still unclear. Both
exocrine and endocrine pancreatic cells are thought to
originate from a multipotential precursor cell (Cho et al.,
1996). The tumor cells may remain in a primitive state
and produce immature hormones, but have such a low
production that the vast majority of MAECs are
nonfunctional (Ohike et al., 2004). Non-dysjunctional
mitosis with dual differentiation or presence of
amphicrine cells within the pancreas are two other
theories regarding the histogenesis of MAECs (Lee et
al., 2013).
A review of all previously published cases of
MAECs (Table 2) showed that a few of these cases are
based on cytology alone (Lee et al., 2013; Sullivan et al.,
2013). The mean age of the resected patients with
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Fig. 5. Cytological and electron microscopic features of a pancreatic MAEC. A. A solid area where tumor cells have nuclei of uniform size is shown.
Distinct nucleoli as well as “salt and pepper” speckled nuclei are observed in some of the tumor cells. B. Tumor cell with mixed ultrastructural features.
Small, intermediate and larger granules are seen in close proximity to the rough endoplasmatic reticulum. Scale bar: 2000 nm.
MAECs fulfilling the inclusion criteria showed an
almost equal age distribution (56% males). Considering
the limited number of cases, our observation may well
be coincidental, particularly because the early series by
Klimstra and Ohike (Klimstra et al., 1994; Ohike et al.,
2004) which, however, were included in our calculation,
showed a female predominance. Interestingly, pure
acinar cell carcinomas (ACC) show a male predilection
by 3 to 1 (Klimstra et al., 2010; La Rosa et al., 2012).
MAECs have a dismal prognosis, with a median
survival after surgical resection of approximately 24
months (La Rosa et al., 2012). In another study of 39
patients with histologically proven ACC, the median
survival was 19 months for all patients, and surgery
remained the best therapy for patients with resectable
tumors (median survival of 36 months compared to 14
months) (Holen et al., 2002).These data indicate that
MAECs may behave more aggressively than true ACCs,
but larger-scale studies with a higher number of patients
are needed to elucidate this further. However, ACCs
have a high recurrence rate even after complete surgical
resection, suggesting that micrometastases may be
present in these patients at time of surgery (Holen et al.,
2002). Chemotherapy and radiation therapy, however, do
not usually improve the outcome significantly (Holen et
al., 2002).
In conclusion, the present case of a pancreatic
MAEC demonstrates the typical morphological,
immunohistochemical and ultrastructural features of this
rare tumor type. Our review of the previously published
MAECs in the English-language literature establishes a
slight male predominance in these tumors, which is
contrary to previously reported small series.
Conflict of interest. The authors report no conflicts of interest. The
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